**PETER H. SCHWARTZ, M.D., Ph.D.**

CURRICULUM VITAE

*Director*, Indiana University Center for Bioethics 410 W 10th St., Ste. 3100

*Professor of Medicine* and *Professor of Bioethics,* Indianapolis, IN 46202

 Indiana University School of Medicine (317) 278-4037

*Professor of Philosophy*, IU School of Liberal Arts, IUPUI phschwar@iu.edu

**EDUCATION**

**POST-GRADUATE:**

**Brigham and Women’s Hospital** Internship and Residency 1999-2003

 Field: Internal Medicine

**GRADUATE:**

**University of Pennsylvania** Master of Arts (MA) 1993

Field: Philosophy

Doctor of Medicine (MD) 1999

Doctor of Philosophy (PhD) 1999

Field: Philosophy

**UNDERGRADUATE:**

**Harvard College** Bachelor of Arts 1987

 Concentration: Biology

 Minor: History

**APPOINTMENTS**

**ACADEMIC:**

**Boston University**

 Adjunct Assistant Professor, Philosophy Department 2001-2004

 Visiting Scholar, Boston Center for the 2004-2005 Philosophy and History of Science

**Indiana University School of Medicine, Department of Medicine**

Division of General Internal Medicine and Geriatrics

 Visiting Assistant Professor of Medicine 2005

 Assistant Professor of Medicine (Tenure Track) 2006-2012

Associate Professor of Medicine (with Tenure) 2012-2022

Scholar in Bioethics 2017-2022

Professor of Medicine 2022-present

Professor of Bioethics 2022-present

**Indiana University School of Liberal Arts, Department of Philosophy**

 Adjunct Assistant Professor of Philosophy 2007

 Assistant Professor of Philosophy (Tenure Track) 2007-2012 Associate Professor of Philosophy (with Tenure) 2012-2022

 Professor of Philosophy 2022-present

**Indiana University Center for Bioethics**

Core Faculty Member 2005-2008

Faculty Investigator 2008-present Acting Director 2012-2013

Interim Director 2016-2017

 Director 2017-present

**ADMINISTRATIVE/PROFESSIONAL:**

**Indiana University Melvin and Bren Simon Cancer Center**

Cancer Prevention and Control Program

Full member 2012-present

**Regenstrief Institute**

Affiliate Scientist, Biomedical informatics 2011-present

**HOSPITAL APPOINTMENTS:**

**Eskenazi Health, Indianapolis, IN**

Previously Wishard Health

Medical Staff 2005-present

**Indiana University Health, Indianapolis, IN**

Previously Clarian Health Partners, Indiana Clinic

Medical Staff 2005-present

**LICENSURE, CERTIFICATION, SPECIALTY BOARD STATUS**

**Licensure and Certification:**

Physician License (Massachusetts) 2004-2005

Drug Enforcement Administration (DEA) #BS8845147 2004-present

Physician License (Indiana) #01059963A 2005-present

Controlled Substances Registry (Indiana) #01059963B 2005-present

**SPECIALTY BOARD STATUS:**

American Board of Internal Medicine Diplomate 2004-2024

**PROFESSIONAL ORGANIZATIONS MEMBERSHIPS**

Philosophy of Science Association, Member 1992-present

American Philosophical Association, Member 1998-present

American College of Physicians, Member 2004-present

American Society for Bioethics and Humanities, Member 2007-present

Society for General Internal Medicine, Member 2008-2015

Society for Medical Decision Making, Member 2010-present

Association of Bioethics Program Directors, Member 2020-present

**PROFESSIONAL HONORS AND AWARDS**

**SERVICE**

Walter C. Randall Award in Biomedical Ethics 2009

American Physiological Society

Named lectureship presented at annual meeting of the American Physiological Society and published in *The Physiologist*.

**OTHER**

Harvard Scholarships Harvard College 1984-1986

John Harvard Scholarship Harvard College 1986-1987

*Magna cum laude* BA degree Harvard College 1987

Theodore Friedmann Prize University of Pennsylvania Medical School 1999

**TEACHING**

**All teaching conducted in person, unless otherwise noted (Virtual, webinar)**

**TEACHING ASSIGNMENTS (FULL COURSES)**

**UNIVERSITY OF PENNSYLVANIA**

UNDERGRADUATE

Philosophy 72 *Biomedical Ethics* Teaching Assistant Fall 1991

 20 students

Philosophy 1 *Introduction to Philosophy* Teaching Assistant Spring 1992

 60 students

**FLORIDA INTERNATIONAL UNIVERSITY**

UNDERGRADUATE

Philosophy 2011 *Philosophical Analysis* Instructor Fall 1998

 20 students

**BOSTON UNIVERSITY**

UNDERGRADUATE

Philosophy 251 *Medical Ethics* Instructor Spring 2002

 40 students

Philosophy 150 *Introduction to Ethics* Instructor Spring 2002

 120 students

Philosophy 160 *Reasoning & Argument* Instructor Spring 2003

 60 students

Philosophy 251 *Medical Ethics* Instructor Spring 2003

 40 students

Philosophy 472 *Philosophy of Biology* Instructor Spring 2004

 20 students

Philosophy 251 *Medical Ethics* Instructor Spring 2004

 40 students

**INDIANA UNIVERSITY SCHOOL OF LIBERAL ARTS,**

**INDIANAPOLIS UNIVERSITY – PURDUE UNIVERSITY, INDIANAPOLIS (IUPUI)**

GRADUATE

Philosophy 696 *Topics in Biomedical Ethics:* Instructor Spring 2006

*Genetics and Enhancement*

 10 students

Philosophy 696 *Topics in Biomedical Ethics:* Instructor Spring 2007

*Genetics, Treatment, Enhancement*

 5 students

Philosophy 600 *Topics in Philosophy:* Instructor Spring 2008

*Philosophy of Medicine*

 11 students

Philosophy 600 *Topics in Philosophy:* Instructor Spring 2009

*Risk, Disease, & Prevention*

7 students

GRADUATE/ UNDERGRADUATE (Cross-listed)

Philosophy 393 / 547 *Biomedical Ethics /* Instructor Spring 2010

 *Foundations of Bioethics*

 27 students

Philosophy 383/ 600 *Topics in Philosophy:* Instructor Fall 2010

 *Biology, Philosophy, and Meaning*

16 students

Philosophy 383/ 696 *Topics in Philosophy:*  Instructor Fall 2011

 *Ethics of Medical Decisions*

 17 students

Philosophy 383/ 696 *Topics in Biomedical Ethics:*  Instructor Spring 2013 *Health and Medical Enhancements*15 students

Philosophy 547 *Foundations of Bioethics* Instructor Fall 201310 students

Philosophy 383/ 696 *Topics in Biomedical Ethics:*  Instructor Spring 2014

*Ethics, Autonomy, and Consent*

16 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Fall 2014

 *Foundations of Bioethics*

 21 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Fall 2015

 *Foundations of Bioethics*

 28 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Fall 2016

 *Foundations of Bioethics*

 26 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Fall 2017

 *Foundations of Bioethics*

 14 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Fall 2018

 *Foundations of Bioethics*

 25 students

Philosophy 383/ 493/ *Topics in Biomedical Ethics:* Instructor Spring 2020

600/ 696 *Ethics, Autonomy, & Consent*
Classroom (2 months) / Virtual (2 months)

15 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Fall 2021

 *Foundations of Bioethics*

 20 students

Philosophy 393/ 547 *Biomedical Ethics /* Instructor Spring 2023

 *Foundations of Bioethics*

 18 students (14 Undergrad / 4 Grad)

Philosophy 590 *Intensive Reading*  Instructor Occasional

(PHIL-P 590) Independent study, usually a single graduate student. 2022 - present

 Offered: Fall 2022 (1 credit, Aubrey Kenefick).

Philosophy 548 *Clinical Ethics Practicum* Instructor Occasional

 Supervise semester-long practicum for 1-2 grad 2013 - present

students per term, as needed: Fall 2013, Spring 2014, (13 times)

Fall 2014, Spring 2015, Fall 2016, Spring 2017, Spring 2018, Fall 2018, Spring 2019, Spring 2020, Spring 2021, Spring 2022, Spring 2023

**INDIANA UNIVERSITY SCHOOL OF MEDICINE**

GRDM-G506 *Responsible Conduct of Translational Research* Instructor Spring 2021

 Virtual (Zoom). 1.5 hrs/ wk x 8 wks (1 credit).

20 students (MD/PhD, PhD, post-docs, faculty)

937P700 *Medical Ethics and Professionalism* Co-Instructor Feb. 2021

 4th Year Elective. Virtual (Zoom). (with Colin

8 medical students. Halverson, PhD)

GRDM-G506 *Responsible Conduct of Translational Research* Instructor Spring 2022

 In person and Zoom. 1.5 hrs/ wk x 8 wks (1 credit).

17 students (MD/PhD, PhD, post-docs, faculty)

937P700 *Medical Ethics and Professionalism* Co-Instructor Feb. 2022

 4th Year Elective. (with Colin

3 medical students. Halverson, PhD)

GRDM-G506 *Responsible Conduct of Translational Research* Instructor Spring 2023

 In person and Zoom. 1.5 hrs/ wk x 8 wks (1 credit).

19 students (MD/PhD, PhD, post-docs, faculty)

937P700 *Medical Ethics and Professionalism* Co-Instructor Feb. 2023

 4th Year Elective. (with Colin

1 medical student. Halverson, PhD)

**PARTICIPATION IN TRAINING GRANTS:**

|  |  |  |  |
| --- | --- | --- | --- |
| **Role** | **Grant** | **PI(s)** | **Dates** |
| Core Faculty | Indiana University – Moi University Academic Research Ethics Partnership (R25 TW006070) | Meslin, Vreeman (IUSM) | 9/25/2008 – 1/31/2017 |
| Core Faculty | Advanced Training in Self-Management Interventions for Serious Chronic Conditions (T32 NR018407) | Rawl, Pressler (IUSON) | 7/1/2019 – 6/30/2024 |
| Mentor | Advanced Fellowship Program in Health Services Research and Development: Learning Health System (Department of Veterans Affairs, Office of Academic Affiliations (OAA), Program # 3K62021B) | Damush, Matthias (VA) | 7/1/2022 – present  |

**TEACHING ADMINISTRATION AND CURRICULUM DEVELOPMENT**

**IU SCHOOL OF MEDICINE**

Curriculum Review: Medical Ethics Thread 2017-2018

Member of team reviewing and revising bioethics training for medical students

New Program Development: 2017-2018

GRDM-G506, “Responsible Conduct of Translational Research”

Led team creating 1-credit course.

Curriculum Revision: GRDM-G504, “Introduction to Research Ethics” 2020

Led team revising 3-credit course

New Program Development: Training Program for New Investigators 2019-present

Member of team developing 1-hour training program

New Program Development: Responsible Conduct of Research (RCR) workshops 2021-present

Assisted development of workshop series to teach RCR (NIH requirement)

**GRANTS / FELLOWSHIP IN TEACHING**

ACTIVE TEACHING GRANTS/ FELLOWSHIPS:

*Developing Character for a Digital World*

Funder: Lilly Endowment PI: Cate 07/01/2019 – 12/31/2021

Description: To develop initiatives to better equip students and faculty for ethical challenges presented by digital technologies

Role: Steering Committee member Effort: 0% Amount: $348,980

*Leveraging Infrastructure to train investigators in patient centered outcomes research in the learning health system (LITI-PCORLHS)*

Funder: AHRQ / PCORI (K12HS026390) PIs: Carroll, Embi 09/30/2018 - 09/29/2023

Description: To train researchers in using the Learning Health Care system to conduct robust patient-centered outcomes research.

Role: Co-Investigator Effort: 0%

COMPLETED TEACHING GRANTS/ FELLOWSHIPS

*Teaching the Ethics and Social Context of Pharmacology*

Medical Education & Curricular Affairs (MECA), Indiana University School of Medicine

 Co-PIs: Gaffney, Schwartz 2006-2007

Description: To develop three Team Based Learning sessions for the medical school Pharmacology course about ethics and policy issues related to development and use of medications.

Role: Co-PI Effort: 0% Amount: $2000.

**INVITED PRESENTATIONS – TEACHING**

**LOCAL**

“Teaching and Training Strategies: Team Based Learning (TBL),” with Meg Gaffney, *Teaching Skills in International Research Ethics Workshop – Epidemic Ethics (TaSkR VII)*, Indiana University School of Medicine, Indianapolis, IN, April 16, 2015.

**NATIONAL**

Panelist for “Challenges and Opportunities in Teaching the Legacy of the Holocaust to Health Professions Students,” Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, *Virtual (Webinar),* Jan. 27, 2021.

**RESEARCH**

**INVITED PRESENTATIONS – RESEARCH**

**LOCAL**

“Defining Dysfunction: Natural Selection, Design, and Drawing a Line,” Philosophy Department, IUPUI, Indianapolis, IN, April 21, 2006.

“Treatment and Enhancement: Human Growth Hormone for Short Stature,” (with Linda DiMeglio), Fairbanks Lecture Series, Charles Warren Fairbanks Center for Medical Ethics, Riley Hospital, Indianapolis, IN, November 28, 2007.

**NATIONAL**

“Proper Function and Recent Selection,” Philosophy of Science Association, Sixteenth Biennial Meeting, Kansas City, MO, October 22, 1998.

“The Extension of Teleology: Demarcating Proper Functions in Biology,” Philosophy Department, California Institute of Technology, Pasadena, CA, January 21, 1999

“Proper Function and Recent Selection,” Philosophy Department, University of Alabama, Birmingham, Birmingham, AB, February 1999

“Proper Function and Recent Selection,” Philosophy Department, University of Miami, Miami, FL, March 2000

“Growth Hormone and Dysfunction,” Philosophy Department, University of Delaware, Newark, Delaware, February 7, 2001

“Genetic Dysfunction and Genetic Disease,” *The New Genetics: Legal, Medical, and Religious Perspectives* symposium, St. Thomas University School of Law, Miami, FL, February 10, 2001

“Functions in Molecular Biology,” Philosophy Department, Boston University, Boston, MA, February 16, 2001

“Comments on Preston’s ‘Artifact Function and Creators’ Intentions’,” American Philosophical Association, Central Division annual meeting, Minneapolis, MN, May 5, 2001.

“Conceptual Analysis in the Function Debate and Beyond,” *Conceptual Analysis and Method in Philosophy of Biology,*Boston Colloquium for Philosophy of Science, Boston University, Boston, MA, November 15, 2002.

“A Concept of Dysfunction in Clinical Medicine,” Philosophy and Medicine conference, University of Alabama, Birmingham, AL, May 15, 2004

“Demarcating Dysfunction: Natural Selection, Design, and Drawing a Line,” Metaphysics and Medicine conference, University of Buffalo, Buffalo, NY, November 13, 2004

“Pluralism about Function,” *Design Principles in Biological Systems*, workshop, Institute for Mathematics and its Applications (IMA), University of Minnesota, Minneapolis, MN. April 23, 2008.

“Dysfunction, Disease, and Daniels: Enhancement and Prevention,” American Philosophical Association – Central Division, Annual Meeting, Chicago, IL, February 17, 2012.

“Small Tumors as Risk Factors rather than Pathology,” Philosophy of Science Association, Annual Meeting, San Diego, CA, November 17, 2012.

**INTERNATIONAL**

“Treating Patients, not Disease,” at conference on *Christopher Boorse and the Philosophy of Medicine*, Hamburg University, Hamburg, Germany, September 10, 2012.

**SERVICE**

**PATIENT CARE/CLINICAL SERVICE:**

**Eskenazi Health System**, previously Wishard Health System

Physician, Adult Primary Care, Primary Care Center 2005-2014

Physician, Adult Primary Care, W. 38th St. Clinic 2014-Present

**GRANTS / FELLOWSHIPS IN SERVICE:**

ACTIVE RESEARCH GRANTS:

*Assessing the Return of Pharmacogenomic Results to Patients in the ADOPT Trial*

Funder: NIH/ NHGRI PI: Skaar 09/01/2021 – 12/31/2023

Description: Supplement to “Implementing Genomic Medicine Through Pragmatic Trials in Diverse and Underserved Populations across Indiana” (5U01HG010245): To study understanding of pharmacogenomics test results by patients in the ADOPT trial (A Depression and Opioid Pragmatic Trial in Pharmacogenetics), part of NHGRI’s Implementing Genomics in Practice (IGNITE) network.

Role: Co-Investigator Effort: 5% Amount: $158,489

*Human Post-Mortem Tissue Conatus*

Funder: Templeton Foundation PI: Sen 05/01/2021 – 04/30/2024

Description: To advance understanding of  the  ways in  which  cells  and  tissues, and the genes in them, strive for life or function to support life even as the body dies; Also, to interrogate related philosophical questions about what it means to be alive, including the nature of death, the unity of organisms, and emergence as a function of living systems.

Role: Co-Investigator Effort: 5% Amount: $1,837,805

*Screening in Primary Care during the COVID-19 Pandemic: Challenges, Responses, and Implementation*

Funder: PCORI PI: Schwartz 11/01/2020 – 01/31/2022

Description: Supplement to CDR-2018C3-14715: To identify barriers, responses, and facilitators for cancer screening (breast, colorectal, cervical, and lung) during the COVID-19 pandemic, based on interviews of leadership, providers, staff, and patients at primary care clinics at IU Health and Eskenazi.

Role: PI Effort: 0% Amount: $309,000

*Measuring the Impact of Providing Personalized Risk Information to Patients and their Providers on Colorectal Cancer Screening Decisions and Uptake*

Funder:PCORI *(*CDR-2018C3-14715) PI: Schwartz 11/01/2019 – 02/29/2024

Description: To test whether providing patients and their providers with personalized messages about the patient’s risk of colorectal cancer increases screening uptake and decision quality, and to identify facilitators and barriers to using this and other approaches to improving colorectal cancer screening.

Role: PI Effort: 30% Amount: $2,800,000

*Precision Health Pharmacogenetics Program*

Funder: IU Precision Health Initiative PI: Skaar 01/01/2019 - 12/31/2023

Description: To support the implementation of pharmacogenetic testing in Indiana.

Role: Co-Investigator Effort: 10%

*Indiana Clinical and Translational Sciences Institute*

Funder: NIH / NCATS (UL1TR002529) PI: Shekhar 05/18/2018 - 04/30/2023

Description: To enhance an institute that facilitates clinical and translational biomedical research within Indiana.

Role: Co-Investigator Effort: 20%

**COMPLETED SERVICE GRANTS/ FELLOWSHIPS**

*Decisions about Cancer Screening in Alzheimer's Disease*

Funder: NIH / NIA (R01AG055424) PI: Fowler 05/01/2017 - 04/30/2022

Description:To measure impact of providing a decision aid to women with dementia regarding screening mammography.

Role: Co-Investigator Effort: 5%

*Precision Health Initiative*

Funder: IU Grand Challenges Program PD: Foroud, Shekhar 09/01/2016 - 02/28/2022

Description: To understand and optimize the prevention, treatment, and health outcomes of human diseases through a precise definition of the genetic, developmental, behavioral and environmental factors that contribute to health.

Role: Co-Investigator Effort: 25%

*Comparing Interventions to Increase Colorectal Cancer Screening in Low-Income and Minority Patients*

Funder: PCORI (CDR-0042-5665) PI: Rawl 07/01/2016 - 05/31/2021

Description: To compare two health system-based interventions, with each other and with usual care, to increase CRC screening rates in a sample of low-income and minority patients who did not attend scheduled colonoscopy.

Role: Co-Investigator Effort: 2%

*Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information*

PCORI (CDR-1403-11040) PI: Schwartz 01/01/2015 - 06/13/2019

Description: To provide clinical evidence and patient input to guide decision aid designers on how to present comparative effectiveness information to patients considering colorectal cancer screening.

Role: PI Effort: 25% Amount: $1,800,000

*Indiana Clinical and Translational Sciences Institute*

NCATS / NIH (UL1TR001108) PI: Schwartz          09/26/2013 – 04/30/2018

Description: To enhance an institute that facilitates clinical and translational biomedical research within Indiana.

Role: Co-Investigator  Effort: 15%-20%

*A Pilot Project to Give Patients Personalized Risk and Benefit Information Regarding Colorectal Cancer Screening*

Center for Law, Ethics, and Applied Research (CLEAR) in Health Information, Indiana University

 PI: Schwartz 11/01/2012 – 10/31/2014

Description: To measure response of patients to personalized risk and benefit information regarding colorectal cancer screening, using online studies of decisions in hypothetical situations and then face-to-face studies of actual decisions in clinical situations.

Role: PI Effort: 0% Amount: $100,000

*Does Knowing about Current or Future Risk of Colorectal Cancer Affect the Uptake of Screening or Test Choice? A Pilot Study of Patients and Providers*

Predictive Health Ethics Research (PredictER) Program, IU Center for Bioethics

 Co-PIs: Imperiale, Schwartz 07/01/2012 – 12/31/2012

Description: To study the opinions of patients and providers to ways of calculating “personalized” risk of colorectal cancer, e.g. using the National Cancer Institute’s web-based Colorectal Cancer Risk Tool.

Role: Co-PI Effort: 0% Amount: $50,000

*Aspiring to Awesome: Advanced Query for Patient Care*

U.S. Office of the National Coordinator for Health Information Technology (90HT0054/01)

 PI: Tierney (PI) 05/01/2011 – 03/31/2014

Description:To establish advanced search tools for the electronic medical record (EMR) and for patients to determine which providers can view specific parts of their record. I serve on the team examining ethical and policy issues involved in providing patients with such granular control of their EMR.

Role: Co-Investigator Effort: 15%

*Cancer Control Career Development Award for Primary Care Physician*

American Cancer Society (CCCDA-10-085-01) PI: Schwartz 07/01/2010 – 06/30/2014

Description: Mentored award to provide support and training for Peter Schwartz, MD, PhD to develop a program of research in cancer control focused on colorectal cancer decision-making.

Role: PI Effort: 50% Amount: $300,000

*Giving Patients Quantitative Information about the Risks of Colorectal Cancer and the Benefits of Screening: A Randomized Trial of a Computer-based Presentation*

Indiana University Health (VFR-320) PI: Schwartz 08/01/10 – 07/31/12

Description: To support the development and testing of a computer-based presentation of quantitative information regarding colorectal cancer screening.

Role: PI Effort: 5% Amount: $80,000

*OPTIMAL Conversations*

Edward R. Roybal Center for Translational Research on Chronic Disease Self-Management Among Vulnerable Older Adults PI: Sachs 2009-2010

Description: To explore the attitudes of older adults to continuing or stopping screening tests.

Role: Co-Investigator Effort: 5%

*Ethical and Social Issues in Comparative Effectiveness Research*

Indiana Humanities Council (#09-1046) Co-Directors: Schwartz, Meslin 2009-2010

Description: To examine ethical and practical challenges for using comparative effectiveness research to improve healthcare and support patient decision making.

Role: Co-Director Effort: 0% Amount: $1300

*Indiana Clinical and Translational Sciences Institute*

NCRR / NIH (UL1RR025761-01) PI: Shekhar 05/01/2008 – 04/30/2013

Description: To establish a new institute that facilitates clinical and translational biomedical research across the state of Indiana.

Role: Co-Investigator Effort: 10%

*Program in Ethical, Legal and Social Issues in Predictive Health Research (PredictER and PredictER II)*

Richard M. Fairbanks Foundation PI: Meslin 09/01/06 – 08/31/12

Description: To support research, policy, and public education focusing on ethical, legal, and social issues that arise in conducting and applying Predictive Health Research.

Role: Co-Investigator Effort: 20%

*General Clinical Research Center*

National Institutes of Health PI: Brater 2006-2008

Description: To support a multi-disciplinary center for clinical research at Indiana University.

Role: Research Subject Advocate Effort: 25%

*Indiana Genomics Initiative (INGEN)*

Lilly Endowment PI: Brater 2000-2008

Description: To support the development of genomics research at Indiana University.

Role: Co-Investigator Effort: 50%

**INVITED PRESENTATIONS – SERVICE**

**NATIONAL**

“Clinical Trial(s) and Error: Acquiring and Applying Evidence,” Dialogues in Research Ethics, School of Medicine, University of Miami, Miami, FL, April 4, 2003

“Risk and Disease,” *Future Horizons for Philosophy of Medicine*, symposium, Boston University Center for the Philosophy and History of Medicine, Boston, MA, Sept. 24, 2007

“Predictive Health Research and Patient Understanding of Risk,” as part of panel on *Ethics and Regulation of Predictive Health Research: A New Translational Paradigm?* American Society for Bioethics and Humanities, Annual Meeting, Washington, DC. October 21, 2007.

“Increased Risk and Medical Decision-Making,” Philosophy of Medicine, roundtable, University of Alabama, Birmingham, AL. March 29, 2008.

“PredictER: Indiana University's Experience in Translating Predictive Health Ethics Research into Practice,”Translating ‘ELSI’: Ethical, Legal and Social Implications of Genomics conference, Cleveland, OH. May 3, 2008.

“Patient Decision Aids and Autonomy,” as part of panel as part of panel on *The Future of Consent*, American Society for Bioethics and Humanities, Annual Meeting, Cleveland, OH. October 26, 2008.

“Ethics and Risk/Benefit in Treatment Decisions about Diabetes,” West Virginia chapter of the American Association of Clinical Endocrinologists (AACE), Annual Meeting, White Sulfur Springs, WV, November 8, 2008.

“Consent and Conversation in Population-Based Genetic Research,” the Walter C. Randall Lecture on Biomedical Ethics, American Physiological Society – Experimental Biology annual meeting, New Orleans, LA, April 21, 2009.

“Ethical Defense of a Nudge Towards Fecal Occult Blood Testing For Colorectal Cancer Screening,” as part of panel on *Ethics and Behavioral Economics in Medicine*, Society for Medical Decision Making, 33rd Annual Meeting, Chicago, IL, October 24, 2011.

“Is it Ethical to Choose for Patients? ‘Nudges’ in Research and Practice,” Dialogues in Research Ethics Seminar, University of Miami Ethics Programs, Miami, FL, February 27, 2012.

“Adding Natural Frequency Data to a Decision Aid for Colorectal Cancer Screening: Results of a Randomized Trial,” Society for Medical Decision Making, 35th Annual Meeting, Baltimore, MD, October 22, 2013.

“Numbers and Patients: Ethical and Empirical Questions,” at conference: *Improving the Quality of Health Care for Women by Expanding Research Opportunities via a National Research Network*, sponsored by the American College of Obstetrician and Gynecologists and the Maternal and Child Health Bureau of the Health Resources and Services Administration, Washington, DC, Sept. 2, 2014.

“Why Talk Risk? Exploring Goals and Ethics of Risk Communication,” Short course (1/2 day) led with Brian J. Zikmund-Fisher, PhD, at Society for Medical Decision Making, 36th Annual Meeting, Miami, FL, October 19, 2014

“Presenting Stool Testing as the Default Option for Colorectal Cancer Screening: Results of a Randomized Trial,” Society for Medical Decision Making, 36th Annual Meeting, Miami, FL, October 21, 2014

“Should Decision Aids Show Numbers to Patients Considering Colorectal Cancer Screening?” (with Tony Williamson) as part of session *Shared Decision Making and Decision Aid Use in the Real World*, Patient Centered Outcomes Research Institute (PCORI), 2015 Annual Meeting, Arlington, VA, October 7, 2015.

“Impact of Personalized and Comparative Risk Information on Decisions about Colorectal Cancer Screening,” Society for Medical Decision Making, 37th Annual Meeting, St. Louis, MO, October 19, 2015.

“Are Numbers Necessary for Informed Consent? From Ethics to Philosophy and Back,” History and Philosophy of Science and Medicine Program, Washington University, St. Louis, MO, October 20, 2015.

“Measuring the Value of Disclosure: The Case of Comparative Risk Data,” Dialogues in Research Ethics Seminar, University of Miami Ethics Programs, Miami, FL, February 17, 2017

“Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information,” as part of panel *Review of Communication and Dissemination of Research portfolio – Presentations by Awardees*, Patient Centered Outcomes Research Institute (PCORI), Advisory Panel on Communication and Dissemination Research Spring 2017 meeting. Washington, DC, April 21, 2017.

“Future Ancillary Uses of Genetic Data in the Electronic Health Record: A ‘Consent to Governance’ Approach,” The 4th ELSI Congress: Genomics and Society: Expanding the ELSI Universe, Farmington, CT, June 6, 2017.

“Clinical Judgment About Disclosure: Should Patients Be Told Their Comparative Risk?” Clinical Judgment Symposium, University of Toronto, Toronto, Ontario, Canada, June 22, 2017.

“Short-Term Impact of Including Quantitative Information in a Decision Aid For Colorectal Cancer Screening,” Society for Medical Decision Making, 39th Annual North American Meeting, Pittsburgh, PA, Oct. 23, 2017

“Layperson Advice Regarding Design, Content, and Use of Decision Aids: A Public Deliberation,” Society for Medical Decision Making, 39th Annual North American Meeting, Pittsburgh, PA, Oct. 25, 2017.

“Improving Ethical Decision-Making without Measuring Decision Quality,” American Society for Bioethics and Humanities, 21st Annual Conference, Pittsburgh, PA, Oct. 27, 2019.

Panelist for “Challenge Studies, Avalanche Testing, and other Approaches to Vaccine Development,” one of a series on *Engineering Solutions for the Next Pandemic: Exploring Ethics Concerns*, presented by the Online Ethics Center (OEC) of the National Academy of Engineering. *Virtual (Webinar)*, June 24, 2020

“Defending Guidelines for Prevention as Ethical Nudges,” Flash presentation, American Society for Bioethics and the Humanities (ASBH), 22nd Annual meeting, *Virtual (Webinar)*, Oct. 15, 2020.

“Reduced Cancer Screening during the Pandemic: What will the Effect be in the Future?” Virtual presentation, Cancer Agencies National Staff Association, *Virtual (Webinar)*, March 9, 2021.

Panelist “At the Crossroad of the Humanities, Medicine, and Technology: A Reading and Discussion of Kurt Vonnegut’s *Fortitude*,” American Society for Bioethics and the Humanities (ASBH), 23rd Annual meeting, *Virtual (Webinar)*, Oct. 13, 2021.

“The Best Insulin is the One the Patient Can Afford,” American Society for Bioethics and the Humanities (ASBH), 23rd Annual meeting, *Virtual (Webinar)*, Oct. 15, 2021.

“Public Deliberation to Guide Decision Aid Design: The Case of Colorectal Cancer Screening,” as part of panel on *Public Deliberation in Medical Decision Making*. Society for Medical Decision Making, 43rd Annual North American meeting, *Virtual (Webinar)*, Oct. 19, 2021.

**INTERNATIONAL**

“Impact of Quantitative Information and a Nudge on Attitudes toward Colorectal Cancer Screening,” Society for Medical Decision Making, 32nd Annual Meeting, Toronto, ON, October 25, 2010.

“Clinical Judgment about Disclosure: Should Patients be Told their Comparative Risk?” Clinical Judgement Symposium, University of Toronto, Toronto, Ontario, Canada, June 22, 2017

“Including Quantitative Information in a Decision Aid does not Improve Colorectal Cancer Screening Decision Quality: Results of a Randomized Trial,” (co-authors Perkins SM, Schmidt KK, Althouse S, Imperiale TF, Rawl SM), Society for Medical Decision Making, 40th Annual North American Meeting, Montreal, QC, Canada, Oct. 15, 2018

“Lack of Value Concordance is not Always Bad: Reasons Patients Give for not Receiving their Preferred Colorectal Cancer Screening Test,” (co-authors Schmidt KK, Thomas A, Cordon S, Price A, Imperiale TF, Perkins SM, Rawl SM) Society for Medical Decision Making, 40th Annual North American Meeting, Montreal, QC, Canada, Oct. 15, 2018

“Trust, Distrust and Danger in the COVID Pandemic: Reflections of a Physician-Bioethicist,” *International Virtual Symposium on The Future of Bioethics in the Post-Pandemic Era*, Center for Law, Governance, and Policy Studies, His Highness Maharajas Government Law College, India. *Virtual (Webinar)*. September 9, 2022.

**PUBLICATIONS**

**TEACHING**

**REFEREED**:

**Articles**

1. **Schwartz PH**, Gaulton G. Addressing the needs of basic and clinical research: analysis of graduates of the University of Pennsylvania MD-PhD program. *Journal of the American Medical Association* (Student section: *msJAMA*) 1999; 281: 96-99.

**Invited Commentaries:**

* + - 1. Feudtner JC, Christakis D, **Schwartz PH**. Ethics and the art of confrontation: Lessons from the John Conley Essays. *Journal of the American Medical Association* (Student section: *Pulse*) 1996; 276: 755-756.

**Abstracts**

1. Khaja MS, Gaffney M, **Schwartz PH**, “Teaching the ethics and social context of pharmacology,” presented at Arnold P. Gold Foundation Symposium, *“How are we teaching humanism in medicine and what is working?”* Chicago, IL, Sept. 27-29, 2007.

**RESEARCH**

**REFEREED**

**Articles**

1. Carlin NF, Halpern R, **Schwartz PH**,Holldobler B. Early learning and the recognition of conspecific cocoons by carpenter ants (*Camponotus* spp.). *Ethology* 1987; 75: 306-316
2. Carlin NF, **Schwartz PH**. Pre-imaginal experience and nestmate brood recognition in the carpenter ant, *C. floridanus*. *Animal Behavior* 1989; 38: 89-95.
3. **Schwartz PH**. Genetic breakthroughs and the limits of medicine:Short stature, growth hormone, and the idea of dysfunction. *St. Thomas Law Review* 2001; 13(4): 965-978.
4. **Schwartz PH**. Moving beyond conceptual analysis in the function debate. *The Monist* 2004; 87(1): 136-153.
5. **Schwartz PH**. Defending the distinction between treatment and enhancement. [Open Peer Commentary] *American Journal of Bioethics* 2005; 5 (3): 17-19.
6. **Schwartz PH**. Defining dysfunction: Natural selection, design, and drawing a line. *Philosophy of Science* 2007; 74(7): 364-385.
7. **Schwartz PH**. Risk and disease. *Perspectives in Biology and Medicine* 2008; 51(3): 320–34.
8. **Schwartz PH**. Reframing the disease debate and defending the Biostatistical Theory, *Journal of Medicine and Philosophy* 2014; 39(6): 572-89. DOI: 10.1093/jmp/jhu039: Link for full text: [http://jmp.oxfordjournals.org/cgi/content/full/jhu039?
ijkey=6i7knhifyArKGRC&keytype=ref](http://jmp.oxfordjournals.org/cgi/content/full/jhu039?ijkey=6i7knhifyArKGRC&keytype=ref)
9. **Schwartz PH**. Progress in defining disease: Improved approaches and increased impact. *Journal of Medicine and Philosophy* 2017; 42(4): 485-502. DOI:10.1093/jmp/jhx012.

**Proceedings papers:**

1. **Schwartz PH**. Proper function and recent selection. *Philosophy of Science* Supplement (Proceedings) 1999; 66: S210-S222.
2. **Schwartz PH**. Small tumors as risk factors not disease. In *Philosophy of Science* Supplement (Proceedings of the 2012 Biennial Meeting of the Philosophy of Science Assocation: Part II: Symposia Papers). Published online July 2014. <http://www.jstor.org/stable/10.1086/678280>

**Book chapters:**

**Schwartz PH**. The Continuing Usefulness account of proper function. In: A. Ariew, R. Cummins, and M. Perlman, eds. *Functions: New Essays in the Philosophy of Psychology and Biology*, Oxford: Oxford Univ. Press, 2002. pp. 244-262.

**Schwartz PH**. Decision and discovery in defining ‘disease.’ In: H. Kincaid and J. McKitrick, eds. *Establishing Medical Reality:  Essays in the Metaphysics and Epistemology of Biomedical Science*, Dordrecht:  Springer, 2007. pp. 47-64.

**Schwartz PH.** Broadening and balancing the goals of medicine: Battling disease and treating the healthy. *Naturalism in philosophy of health*, ed. E. Giroux. Springer. 2016. pp. 199-208.

**SERVICE**

**REFEREED**

**Articles:**

1. **Schwartz PH**. Silence about screening. [Open Peer Commentary] *American Journal of Bioethics* 2007; 7 (7): 46-48.
2. **Schwartz PH**, Meslin EM. The ethics of information: Absolute risk reduction and patient understanding of screening. *Journal of General Internal Medicine* 2008; 23(6): 867-870.
3. **Schwartz PH**. Disclosure and rationality: Comparative risk information and decision-making about prevention. *Theoretical Medicine and Bioethics* 2009; 30(3): 199-213. doi:10.1007/s11017-009-9111-7.
4. **Schwartz PH**. The value of information and the ethics of personal-genomic screening. [Open Peer Commentary] *American Journal of Bioethics* 2009; 9 (4): 26-27**.**
5. **Schwartz PH**. Autonomy and consent in biobanks. *The Physiologist* 2010; 53 (1): 1, 3-7.
6. **Schwartz PH**. Questioning the quantitative imperative: Decision aids, prevention, and the ethics of disclosure. *Hastings Center Report* 2011; 41(2): 30-39.
7. **Schwartz PH**. Discounting a surgical risk: Data, understanding, and gist. [Case Commentary] *Virtual Mentor: American Medical Association Journal of Ethics,* July 2012; 14(7): 532-538. Available at: <http://virtualmentor.ama-assn.org/2012/07/ecas1-1207.html>
8. **Schwartz PH**. Child safety, absolute risk, and the prevention paradox,” *Hastings Center Report* July-Aug 2012; 42(4); 20-23. DOI: 10.1002/hast.37. Available online at: <http://onlinelibrary.wiley.com/doi/10.1002/hast.37/pdf>
9. **Schwartz PH**, Edenberg E, Barrett PR, Perkins SM, Meslin EM, Imperiale TF. Patient understanding of benefits, risks, and alternatives to screening colonoscopy, *Family Medicine* 2013; 45(2): 83-9.
10. Torke AM, **Schwartz PH**, Holtz LR, Montz K, Sachs GA. Older adults and forgoing cancer screening: ‘I think it would be strange.’ *JAMA Intern Med.* 2013; 173(7): 526-531. DOI:10.1001/jamainternmed.2013.2903.
11. Torke AM, **Schwartz PH**, Holtz LR, Montz K, Sachs, GA. Caregiver perspectives on cancer screening for persons with dementia: “Why put them through it?” *J Am Geriatr Soc.* 2013;6(8):1309-1314.
12. Meslin EM, Alpert SA, Carroll AE, Odell JD, Tierney, WM, **Schwartz PH**. Giving patients granular control of personal health information: Using an ethics ‘Points to Consider’ to inform informatics system designers. *International Journal of Medical Informatics* 2013; 82: 1136-1143.
13. Meslin EM, Carroll AE, **Schwartz PH**, Kennedy S. Is the social contract incompatible with the social safety net? Revisiting a key philosophical tradition. *Journal of Civic Literacy* 1(1). Published online July 1, 2014. Available at: <https://journals.iupui.edu/index.php/civiclit/article/view/16668/17201>
14. Tierney WM, Alpert SA, Byrket A, Caine K, Leventhal JC, Meslin EM, **Schwartz PH**. Provider responses to patients controlling access to their electronic health records: a prospective cohort study in primary care. *Journal of General Internal Medicine* 2015; 30 (Suppl 1): S31–7. DOI: 10.1007/s11606-014-3053-0
15. Leventhal JC, Cummin JA, **Schwartz PH**, Martin DK, Tierney WM. Designing a system for patients controlling providers’ access to their electronic health records: organizational and technical challenges. *Journal of General Internal Medicine* 2015; 30 (Suppl 1): S17-24. DOI: 10.1007/s11606-014-3055-y
16. **Schwartz PH**, Caine K, Alpert SA, Meslin EM, Carroll AE, Tierney WM. Patient preferences to control access to their electronic health records in a prospective cohort study in primary care. *Journal of General Internal Medicine* 2015; 30 (Suppl 1): S25-30. DOI: 10.1007/s11606-014-3054-z
17. Meslin EM, **Schwartz PH**. How bioethics principles can aid design of electronic health records to accommodate patient granular control. *Journal of General Internal Medicine* 2015; 30 (Suppl 1): S3-6. doi:10.1007/s11606-014-3062-z.
18. Cho M, Taylor H, McCormick J, Barnard D, Boyle M, Capron A, Dorfman E, Havard K, Reider C, Sadler J, **Schwartz PH**, Anderson N, Danis M, Sharp R, Wilfond B. Building a central repository for research ethics consultation data: a proposal for a standard data collection tool. *Clinical and Translational Science* 2015; 8(4): 376-387.
19. **Schwartz PH.** Placebos, full disclosure, and trust: the risks and benefits of disclosing risks and benefits. [Open Peer Commentary] *American Journal of Bioethics*. 2015 Oct; 15(10): 13-4. doi: 10.1080/15265161.2015.1074315.
20. Meslin EM, Rager J, **Schwartz PH**, Quaid KA, Gaffney MA, Duke J, Tierney WH. Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest. *Clinical and Translational Medicine* (2015) 4: 36-45. doi:10.1186/s40169-015-0077-y
21. **Schwartz PH.** Comparative risk: Good or bad heuristic? [Open Peer Commentary] *American Journal of Bioethics* 2016; 16(5): 20-22.
22. **Schwartz PH**, Perkins SM, Schmidt KK, Muriello PF, Althouse S, Rawl SM. Providing quantitative information and a nudge to undergo stool testing in a colorectal cancer screening decision aid. *Med Decision Making* 2017; 37(6): 688-702. doi:[10.1177/0272989X17698678](https://doi.org/10.1177/0272989X17698678)
23. **†**Rager JB, **Schwartz PH**, Defending opioid treatment agreements: Disclosure, not promises. *Hastings Center Report* 2017; 47(3): 24-33. doi:10.1002/hast.702
24. Fowler NR, Schonber MA, Sachs GA, **Schwartz PH**, Gao S, Lane KA, Inger L, Torke AM. Supporting breast cancer screening decisions for caregivers of older women with dementia: study protocol for a randomized controlled trial. *Trials* 2018; 678. [doi:10.1186/s13063-018-3039-z](https://doi.org/10.1186/s13063-018-3039-z)
25. **Schwartz PH**, Imperiale TF, Perkins SM, Schmidt KK, Althouse S, Rawl SM. Impact of including quantitative information in a decision aid for colorectal cancer screening: A randomized controlled trial. *Patient Education and Counseling* 2019; 102(3): 494-502. [doi: 10.1016/j.pec.2018.11.010](https://doi.org/10.1016/j.pec.2018.11.010).
26. Hartsock JA, **Schwartz PH**, Waltz AC, Ott MA. Anticipatory waivers of consent for pediatric biobanking. *Ethics of Human Research* 2019; 41(2): 14-21. doi: 10.1002/eahr.500008.PMID: 30895753
27. **†**Kasperbauer TJ, **Schwartz PH**. Measuring understanding and respecting trust in biobank consent. [Open Peer Commentary] *American Journal of Bioethics* 2019; 19(5): 29-31.
28. **†**Kasperbauer TJ, **Schwartz PH**. Genetic data aren’t so special: Causes and implications of re-identification. *Hastings Center Report* 2020; 50 (5): 30-39. doi: 10.1002/hast.1183.
29. **†**Kasperbauer TJ, Schmidt KK, Thomas A, Perkins SM, **Schwartz PH**. Incorporating biobank consent into a healthcare setting: Challenges for patient understanding. *AJOB Empirical Bioethics* 2021; 12(2): 113-122. doi: 10.1080/23294515.2020.1851313.
30. **Schwartz PH**, O’Doherty KC, Bentley C, Schmidt KK, Burgess MM. Layperson views about the design and evaluation of decision aids about colorectal cancer screening: A public deliberation. *Medical Decision Making* 2021 (July); 41(5): 527-539. doi: [10.1177/0272989X21998980](https://doi.org/10.1177/0272989x21998980).
31. Katz ML, Emerson B, Champion VL, **Schwartz PH**, Imperiale TF, Fatima H, Paskett ED, Perkins SM, Tong Y, Gebregziabher N, Krier C, Tharp K, Malloy C, Strom S, Rawl SM. Process evaluation of a mailed interactive educational DVD in a comparative effectiveness trial to promote colorectal cancer screening. *Health Promotion Practice*. Published online ahead of print, 2021 Aug 3. doi:10.1177/15248399211027831
32. †Kasperbauer TJ, Halverson C, Garcia Sierra A, Schmidt KK, **Schwartz, PH**. Biobank participants’ attitudes toward requiring understanding for biobank consent. *Ethics & Human Research* 2022; 44(1): 18-28. doi: 10.1002/eahr.500114
33. †Kasperbauer TJ, Waltz A, Hawryluk B, Moore C, Schmidt KK, **Schwartz PH**. Collecting biospecimens and obtaining biobank consent from patients in a healthcare setting: Practical and ethical considerations. *Academic Medicine* 2022; 97(1): 62–68. doi:10.1097/ACM.0000000000004418
34. †Kasperbauer TJ, Halverson CME, Garcia A, **Schwartz PH**. Biobank participants’ attitudes toward data sharing and privacy: The role of trust in reducing perceived risks. *Journal of Empirical Research on Human Research Ethics* 2022;17(1-2):167-176. doi:10.1177/15562646211055282.
35. Fatima H, Wajid M, Krier C, Champion V, Carter-Harris L, Shedd-Steele R, Imperiale TF, **Schwartz PH**, Strom S, Magnarella M, Rawl SM. Development of a Computer-Tailored Intervention/Decision Aid to Increase Colorectal Cancer Screening in Health Systems. *Cureus* 2022; 14(3): e23372. doi:10.7759/cureus.23372.
36. †Rager JB, Althouse S, Perkins SM, Schmidt KK, **Schwartz PH**. Measuring the impact of quantitative information on patient understanding: Approaches for assessing the adequacy of patient knowledge about colorectal cancer screening. *Medical Decision Making Policy & Practice* 2022; 7(2): 1-12. doi: 10.1177/23814683221140122.
37. **Schwartz PH**, Sachs G. Rethinking decision quality: Measurement, meaning, and bioethics. *Hastings Center Report* 2022; 52(6): 13-22. doi: 10.1002/hast.1443.
38. **Schwartz** **PH**, Hartsock JA. Selling clinical biospecimens: Guidance for researchers and private industry. *Journal of Law, Medicine, and Ethics* (in press). Accepted April 2022.
39. Being revised for resubmission: Waltz A, Johnson B, **Schwartz PH**. Clarifying and limiting responsibilities: Guidelines for investigators and the IRB on return of clinically relevant research results to participants. Submitted to *Ethics & Human Research*, Oct. 2022. Being revised for re-submission (March 2023).
40. Under review: Doyle TA, Schmidt KK, Halverson CME, Olivera J, Garcia A, Shugg TA, Skaar TC, **Schwartz PH**. Patient understanding of pharmacogenomic test results in clinical care. Under review at *Patient Education and Counseling*. Submitted Jan 2023.

**Book chapters:**

1. Meslin EM and **Schwartz PH**. To be or not to be – A research subject. In T. Kushner, ed., *Surviving Health Care: A Manual for Patients and their Families*. Cambridge: Cambridge University Press. 2010. Available at: <http://hdl.handle.net/1805/2501>
2. **Schwartz PH**. Do the numbers help patients decide? Ethical and empirical challenges for evaluating the impact of quantitative information. In *Numerical Reasoning in Judgments and Decision Making about Health,* eds.B.L. Anderson and J. Schulkin, Cambridge: Cambridge Univ. Press. 2014. pp. 252-280.

**Letters to the editor:**

1. **Schwartz PH**. Stem cells: Biopsy on frozen embryos. *Hastings Center Report* 2007; 37 (1): 7-8.

**Editorials:**

* + - 1. **Schwartz PH**. Ethics of gene therapy in the military: Promise and potential problems. *Molecular Therapy* 2020; 28 (4); 987-988.
			2. †Halverson CME, Pratt VM, Skaar TC, **Schwartz PH**. Ending the pharmacogenomic gag rule: The imperative to report all results. *Pharmacogenomics* 2021 Mar; 22(4):191-193. <https://doi.org/10.2217/pgs-2020-0172>
			3. **Schwartz PH**. The Framing Dilemma: Quantitative information, shared decision making, and nudging. *Medical Decision Making* 2022; 42(6): 726-728. doi: 10.1177/0272989X221109830

**Book Reviews:**

1. **Schwartz PH**. “Better living through neurochemistry?” Brief review of *Hard Science, Hard Choices:  Facts, Ethics, and Policies Guiding Brain Science Today*, by SJ Ackerman. *Wilson Quarterly* 2006; 30 (3): 110-111.
2. **Schwartz PH**. “Finding the proper place for prevention: Review of *Prevention vs. Treatment: What’s the Right Balance?* eds. Halley S. Faust and Paul T. Menzel,” *American Journal of Bioethics* 2012; 12(9): 60-61.

**Abstracts:**

1. **Schwartz PH**, Imperiale TF, Kloss HN, Perkins SM, Rawl SM, Sachs GA, Meslin EM, “Impact of quantitative information and a nudge on attitudes toward colorectal cancer screening,” *Medical Decision Making* 2011;31: E123-E124. DOI:10.1177/0272989X10393877.

Available at: <http://mdm.sagepub.com/content/31/1/E54.full>

1. Torke AM, **Schwartz PH**, Holtz L, Montz K, Sachs GA, “Perspectives of older adults toward stopping cancer screening,” *Journal of the American Geriatrics Society* 2011; 59: S9.
2. Torke AM, **Schwartz PH**, Holtz L, Montz K, Sachs GA, “Cancer screening in patients with dementia: family caregiver perspectives,” *Journal of the American Geriatrics Society* 2012; 60: S122-S123.
3. **Schwartz PH**, Muriello PF, Perkins SM, Schmidt KK, Rawl SM, “Adding natural frequency data to a decision aid for colorectal cancer screening: Results of a randomized trial,” *Medical Decision Making* 2014: E29-E30. D01 10.1177/0272989X13519751. Available at <http://mdm.sagepub.com/content/34/2/E1>. Accessed 2014-2-17.
4. **Schwartz PH**, Perkins SM, Schmidt KK, Muriello PF, Althouse S, Rawl SM “Presenting Stool Testing as the Default Option for Colorectal Cancer Screening: Results of a Randomized Trial,” *Medical Decision Making* Jan. 2015; 35: E39
5. **Schwartz PH**, Schmidt KK, Muriello PF, Cox AD, Cox DS, “Impact of Personalized and Comparative Risk Information on Decisions about Colorectal Cancer Screening,” *Medical Decision Making* July 2016; 36 (5): E301-E302.
6. **Schwartz PH**, Schmidt KK, Muriello PF, Imperiale T, Perkins SM, Rawl SM, “Value Judgments and Tradeoffs in Choosing Quantitative Information and Framing for a Decision Aid,” *Medical Decision Making* Jan 2017; 37 (1) E148-E149.
7. **Schwartz PH**, Schmidt KK, Muriello PF, Imperiale T, Perkins SM, Althouse S, Rawl SM, “Short-Term Impact of Including Quantitative Information in a Decision Aid for Colorectal Cancer Screening,” *Medical Decision Making* Jan 2018; 38(1): E254-E255.
8. **Schwartz PH**, Schmidt KK, O’Doherty K, Bentley C, Zikmund-Fisher BJ, Burgess M. “Layperson Advice Regarding Design, Content, and Use of Decision Aids: A Public Deliberation,” *Medical Decision Making* Jan 2018; 38(1): E340-E341.
9. **Schwartz PH**, Perkins SM, Althouse S, Imperiale T, Schmidt KK, Rawl SM. “Including Quantitative Information in a Decision Aid does not Improve Colorectal Cancer Screening Decision Quality: Results of a Randomized Trial,” *Medical Decision Making* Jan 2019; 39 (1): E243-E244.
10. **Schwartz PH,** Schmidt KK, Thomas A, Cordon S, Price A, Imperiale T, Perkins SM, Rawl SM, “Lack of Value Concordance is not Always Bad: Reasons Patients Give for not Receiving their Preferred Colorectal Cancer Screening Test,” *Medical Decision Making* Jan 2019; 39 (1): E261-E262.

**Other:**

* + - 1. **Schwartz PH**, Imperiale TF, Perkins SM, Burgess MM, O’Doherty KC, Schmidt KK, Althouse S, Bentley C, Rawl SM. *Using Numbers in a Decision Aid to Describe Risks and Benefits of Colorectal Cancer Screening Options.* 2020. Patient-Centered Outcomes Research Institute (PCORI). <https://doi.org/10.25302/05.2020.CDR.140311040>

**NON-REFEREED**

**White papers (online):**

1. Barrett PR, Meslin EM, **Schwartz PH**, Girod J, Odell JD, Quaid K, Wolf J. Report from the PredictER Expert Panel Meeting, November 2, 2007. [Indiana University Center for Bioethics, January 7, 2008]Available at:<http://hdl.handle.net/1805/1711>

**Blogs:**

1. **Schwartz PH,** [Translating ELSI – From a conference at Case Western to the world](http://predicter.blogspot.com/2008/05/translating-elsi-from-conference-at.html), PredictER blog, May 8, 2008, Available at: <http://predicter.blogspot.com/2008/05/translating-elsi-from-conference-at.html>
2. **Schwartz PH,** [Predictive health, insurance & security: A spiritual perspective](http://predicter.blogspot.com/2008/12/predictive-health-insurance-security.html), PredictER blog, December 18, 2008, Available at: <http://predicter.blogspot.com/2008/12/predictive-health-insurance-security.html>
3. **Schwartz PH, “**Follow the money: the Affordable Care Act, not the Subsidized Care Act,” July 3, 2012, Available at: <http://iucb.wordpress.com/2012/07/03/follow-the-money-the-affordable-care-act-not-the-subsidized-care-act/>
4. **Schwartz PH, “**Tragedy and choice,” Nov. 16, 2013. Available at: <http://iucb.wordpress.com/2013/11/16/tragedy-and-choice/>
5. **Schwartz PH,** “Facing hard truths about the Holocaust, medical science, and bioethics,” IU Center for Bioethics blog, Available at: <https://medicine.iu.edu/blogs/bioethics/facing-hard-truths-about-the-holocaust-medical-science-and-bioethics>
6. **Schwartz PH,** “Outlaw tennis: Ethically violating a COVID closure,” IU Center for Bioethics blog, May 26, 2020. Available at: <https://medicine.iu.edu/blogs/bioethics/ethically-violating-a-covid-closure>
7. **Schwartz PH,** “Your behavior, your health, our pandemic,” IU Center for Bioethics blog, July 17, 2020. Available at: <https://medicine.iu.edu/blogs/bioethics/your-behavior-your-health-our-pandemic>
8. **Schwartz PH,** “Vaccine fairness - The big picture,” IU Center for Bioethics blog, Feb. 1, 2021. Available at: <https://medicine.iu.edu/blogs/bioethics/vaccine-fairness>

**Letters to the editor (Newspapers):**

1. **Schwartz PH**. Patient’s wishes, comfort are the main concern. In: Matters of life and death: Three bioethicists lay out guidelines for making decisions that impact the quality and the sanctity of life. *The Indianapolis Star*, April 24, 2005, page E1.
2. **Schwartz PH**. Everyone should embrace new stem cell technique. *The Indianapolis Star*, Sept. 3, 2006. page E4.
3. **Schwartz PH** and Meslin EM. New technique is a promising pathway to cures. *The Indianapolis Star*, Dec. 23, 2007. page E1.